A recent observational study linked the signalling pathway of the serum receptor activator of nuclear factor kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG) to breast volume changes during pregnancy in healthy women, implicating potential alterations in breast cancer risk [18]. Here, TNFRSF11B is linked to breast carcinoma.